Review





Similar Products

comparison of safety and efficacy of coronary drug coated balloon dcb  (B. Braun)
86
B. Braun comparison of safety and efficacy of coronary drug coated balloon dcb
Procedural considerations and differences between <t>DCB</t> and DES. DES, drug-eluting stent; <t>DCB,</t> <t>drug-coated</t> balloon; PCI, percutaneous coronary intervention.
Comparison Of Safety And Efficacy Of Coronary Drug Coated Balloon Dcb, supplied by B. Braun, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dcb+balloon/pmc12971709-66-0-43?v=B.+Braun
Average 86 stars, based on 1 article reviews
comparison of safety and efficacy of coronary drug coated balloon dcb - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
jo urn al pr e p roo f 4 • drug coated balloon dcb  (Boston Scientific Corporation)
86
Boston Scientific Corporation jo urn al pr e p roo f 4 • drug coated balloon dcb
Procedural considerations and differences between <t>DCB</t> and DES. DES, drug-eluting stent; <t>DCB,</t> <t>drug-coated</t> balloon; PCI, percutaneous coronary intervention.
Jo Urn Al Pr E P Roo F 4 • Drug Coated Balloon Dcb, supplied by Boston Scientific Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dcb+balloon/pm41520819-578-181-215?v=Boston+Scientific+Corporation
Average 86 stars, based on 1 article reviews
jo urn al pr e p roo f 4 • drug coated balloon dcb - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
surveiltm drug coated balloon “dcb  (Abbott Laboratories)
86
Abbott Laboratories surveiltm drug coated balloon “dcb
Procedural considerations and differences between <t>DCB</t> and DES. DES, drug-eluting stent; <t>DCB,</t> <t>drug-coated</t> balloon; PCI, percutaneous coronary intervention.
Surveiltm Drug Coated Balloon “Dcb, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dcb+balloon/sec_filing____924717_slash_000095017023026912_slash_srdx___ex99_1-6-78-119?v=Abbott+Laboratories
Average 86 stars, based on 1 article reviews
surveiltm drug coated balloon “dcb - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
drug coated balloon dcb angioplasty  (Boston Scientific Corporation)
86
Boston Scientific Corporation drug coated balloon dcb angioplasty
The risk of occlusion after procedure during the follow-up. ( A ) Before matching, the atherectomy group did not see a decrease in the risk of occlusion from the reference of the PTA ± stent group (HR 0.99, p = 0.984). ( B ) After 1:3 propensity matching, univariate analysis demonstrated that the atherectomy group did not see a decrease in the risk of occlusion from the reference of the PTA ± stent group (HR 1.1, p = 0.852) ( C ) After 1:3 propensity matching, multivariate analysis demonstrated that the atherectomy group saw a significant decrease in the risk of occlusion from the reference of the PTA ± stent group (HR < 0.01, *** p < 0.001). However, use of a <t>DCB</t> or diabetes did not affect the risk of occlusion. PTA ± stent = balloon <t>angioplasty</t> and/or stenting; HR = hazard ratio; DCB = drug-coated balloon.
Drug Coated Balloon Dcb Angioplasty, supplied by Boston Scientific Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dcb+balloon/pmc12525062-152-1-12?v=Boston+Scientific+Corporation
Average 86 stars, based on 1 article reviews
drug coated balloon dcb angioplasty - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
drug coated balloon dcb percutaneous transluminal angioplasty catheter device trade name  (Philips Healthcare)
86
Philips Healthcare drug coated balloon dcb percutaneous transluminal angioplasty catheter device trade name
The risk of occlusion after procedure during the follow-up. ( A ) Before matching, the atherectomy group did not see a decrease in the risk of occlusion from the reference of the PTA ± stent group (HR 0.99, p = 0.984). ( B ) After 1:3 propensity matching, univariate analysis demonstrated that the atherectomy group did not see a decrease in the risk of occlusion from the reference of the PTA ± stent group (HR 1.1, p = 0.852) ( C ) After 1:3 propensity matching, multivariate analysis demonstrated that the atherectomy group saw a significant decrease in the risk of occlusion from the reference of the PTA ± stent group (HR < 0.01, *** p < 0.001). However, use of a <t>DCB</t> or diabetes did not affect the risk of occlusion. PTA ± stent = balloon <t>angioplasty</t> and/or stenting; HR = hazard ratio; DCB = drug-coated balloon.
Drug Coated Balloon Dcb Percutaneous Transluminal Angioplasty Catheter Device Trade Name, supplied by Philips Healthcare, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dcb+balloon/fda_document____cdrh_docs_slash_pdf16_slash_p160049s015b-4-5-29?v=Philips+Healthcare
Average 86 stars, based on 1 article reviews
drug coated balloon dcb percutaneous transluminal angioplasty catheter device trade name - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
drug coated balloon dcb  (B. Braun)
86
B. Braun drug coated balloon dcb
The risk of occlusion after procedure during the follow-up. ( A ) Before matching, the atherectomy group did not see a decrease in the risk of occlusion from the reference of the PTA ± stent group (HR 0.99, p = 0.984). ( B ) After 1:3 propensity matching, univariate analysis demonstrated that the atherectomy group did not see a decrease in the risk of occlusion from the reference of the PTA ± stent group (HR 1.1, p = 0.852) ( C ) After 1:3 propensity matching, multivariate analysis demonstrated that the atherectomy group saw a significant decrease in the risk of occlusion from the reference of the PTA ± stent group (HR < 0.01, *** p < 0.001). However, use of a <t>DCB</t> or diabetes did not affect the risk of occlusion. PTA ± stent = balloon <t>angioplasty</t> and/or stenting; HR = hazard ratio; DCB = drug-coated balloon.
Drug Coated Balloon Dcb, supplied by B. Braun, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dcb+balloon/pmc12441523-7-65-70?v=B.+Braun
Average 86 stars, based on 1 article reviews
drug coated balloon dcb - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
optilume ® drug-coated balloon (dcb)  (Laborie Medical Technologies Inc)
90
Laborie Medical Technologies Inc optilume ® drug-coated balloon (dcb)
Intraoperative images of cystoscopic evaluation pre-dilation ( A ), deployment of the <t>Optilume</t> balloon ( B ), and post-dilation tissue changes ( C )
Optilume ® Drug Coated Balloon (Dcb), supplied by Laborie Medical Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dcb+balloon/pmc12275432-15-10-15?v=Laborie+Medical+Technologies+Inc
Average 90 stars, based on 1 article reviews
optilume ® drug-coated balloon (dcb) - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


Procedural considerations and differences between DCB and DES. DES, drug-eluting stent; DCB, drug-coated balloon; PCI, percutaneous coronary intervention.

Journal: Frontiers in Cardiovascular Medicine

Article Title: Drug-coated balloons in complex large-vessel coronary artery disease: a comprehensive review of current evidence and future perspectives

doi: 10.3389/fcvm.2026.1731952

Figure Lengend Snippet: Procedural considerations and differences between DCB and DES. DES, drug-eluting stent; DCB, drug-coated balloon; PCI, percutaneous coronary intervention.

Article Snippet: Comparison of Safety and Efficacy of Coronary Drug-coated Balloon (DCB) Combined with Spot Stenting of Drugeluting Stent (DES) vs. Secondgeneration DES for Treating Diffuse Coronary Artery Lesion (Clinicaltrials.gov NCT03817801 ) , Prospective, randomized clinical trial (DCB + DES vs. DES) , SeQuent Please (Braun, Melsungen, Berlin, Germany) , LLL , 2.5–4.0 mm , 140 , 36.

Techniques:

Ongoing clinical trials on DCBs for de novo large-vessel CAD. BRS, bioresorbable scaffold; CAD, coronary artery disease; DES, drug-eluting stent; DCB, drug-coated balloon; FFR, fractional flow reserve; LLL, late lumen loss; MACE, major adverse cardiac event; MB, main branch; NACE, net adverse cardiac events; PCI, percutaneous coronary intervention; RVD, reference vessel diameter; SB, side branch; TLF, target lesion failure; TVF, target vessel failure.

Journal: Frontiers in Cardiovascular Medicine

Article Title: Drug-coated balloons in complex large-vessel coronary artery disease: a comprehensive review of current evidence and future perspectives

doi: 10.3389/fcvm.2026.1731952

Figure Lengend Snippet: Ongoing clinical trials on DCBs for de novo large-vessel CAD. BRS, bioresorbable scaffold; CAD, coronary artery disease; DES, drug-eluting stent; DCB, drug-coated balloon; FFR, fractional flow reserve; LLL, late lumen loss; MACE, major adverse cardiac event; MB, main branch; NACE, net adverse cardiac events; PCI, percutaneous coronary intervention; RVD, reference vessel diameter; SB, side branch; TLF, target lesion failure; TVF, target vessel failure.

Article Snippet: Comparison of Safety and Efficacy of Coronary Drug-coated Balloon (DCB) Combined with Spot Stenting of Drugeluting Stent (DES) vs. Secondgeneration DES for Treating Diffuse Coronary Artery Lesion (Clinicaltrials.gov NCT03817801 ) , Prospective, randomized clinical trial (DCB + DES vs. DES) , SeQuent Please (Braun, Melsungen, Berlin, Germany) , LLL , 2.5–4.0 mm , 140 , 36.

Techniques: Clinical Proteomics

Drug-Coated Balloons in Complex Large-Vessel Coronary Artery Disease: A Comprehensive Review of Current Evidence and Future Perspectives. DAPT, dual antiplatelet therapy; DES, drug-eluting stent; DCB, drug-coated balloon; LLL, late lumen loss; MACE, major adverse cardiac event; PCI, percutaneous coronary intervention; POBA, plain old balloon angioplasty; SAPT, single antiplatelet therapy; SB, side branch; TLF, target lesion failure; TLR, target lesion revascularization.

Journal: Frontiers in Cardiovascular Medicine

Article Title: Drug-coated balloons in complex large-vessel coronary artery disease: a comprehensive review of current evidence and future perspectives

doi: 10.3389/fcvm.2026.1731952

Figure Lengend Snippet: Drug-Coated Balloons in Complex Large-Vessel Coronary Artery Disease: A Comprehensive Review of Current Evidence and Future Perspectives. DAPT, dual antiplatelet therapy; DES, drug-eluting stent; DCB, drug-coated balloon; LLL, late lumen loss; MACE, major adverse cardiac event; PCI, percutaneous coronary intervention; POBA, plain old balloon angioplasty; SAPT, single antiplatelet therapy; SB, side branch; TLF, target lesion failure; TLR, target lesion revascularization.

Article Snippet: Comparison of Safety and Efficacy of Coronary Drug-coated Balloon (DCB) Combined with Spot Stenting of Drugeluting Stent (DES) vs. Secondgeneration DES for Treating Diffuse Coronary Artery Lesion (Clinicaltrials.gov NCT03817801 ) , Prospective, randomized clinical trial (DCB + DES vs. DES) , SeQuent Please (Braun, Melsungen, Berlin, Germany) , LLL , 2.5–4.0 mm , 140 , 36.

Techniques:

The risk of occlusion after procedure during the follow-up. ( A ) Before matching, the atherectomy group did not see a decrease in the risk of occlusion from the reference of the PTA ± stent group (HR 0.99, p = 0.984). ( B ) After 1:3 propensity matching, univariate analysis demonstrated that the atherectomy group did not see a decrease in the risk of occlusion from the reference of the PTA ± stent group (HR 1.1, p = 0.852) ( C ) After 1:3 propensity matching, multivariate analysis demonstrated that the atherectomy group saw a significant decrease in the risk of occlusion from the reference of the PTA ± stent group (HR < 0.01, *** p < 0.001). However, use of a DCB or diabetes did not affect the risk of occlusion. PTA ± stent = balloon angioplasty and/or stenting; HR = hazard ratio; DCB = drug-coated balloon.

Journal: Journal of Clinical Medicine

Article Title: Percutaneous Atherectomy Versus Balloon Angioplasty/Stenting in the Treatment of Femoropopliteal Arterial Occlusive Disease

doi: 10.3390/jcm14196926

Figure Lengend Snippet: The risk of occlusion after procedure during the follow-up. ( A ) Before matching, the atherectomy group did not see a decrease in the risk of occlusion from the reference of the PTA ± stent group (HR 0.99, p = 0.984). ( B ) After 1:3 propensity matching, univariate analysis demonstrated that the atherectomy group did not see a decrease in the risk of occlusion from the reference of the PTA ± stent group (HR 1.1, p = 0.852) ( C ) After 1:3 propensity matching, multivariate analysis demonstrated that the atherectomy group saw a significant decrease in the risk of occlusion from the reference of the PTA ± stent group (HR < 0.01, *** p < 0.001). However, use of a DCB or diabetes did not affect the risk of occlusion. PTA ± stent = balloon angioplasty and/or stenting; HR = hazard ratio; DCB = drug-coated balloon.

Article Snippet: For drug-coated balloon (DCB) angioplasty, IN.PACTTM AdmiralTM (Medtronic, Minneapolis, MN, USA), RangerTM (Boston Scientific, Marlborough, MA, USA), and Lutonix ® (BD, Franklin Lakes, NJ, USA) were used.

Techniques:

Intraoperative images of cystoscopic evaluation pre-dilation ( A ), deployment of the Optilume balloon ( B ), and post-dilation tissue changes ( C )

Journal: BMC Urology

Article Title: Optilume balloon dilation for radiation induced posterior urethral stenosis: a multi-institutional experience

doi: 10.1186/s12894-025-01829-0

Figure Lengend Snippet: Intraoperative images of cystoscopic evaluation pre-dilation ( A ), deployment of the Optilume balloon ( B ), and post-dilation tissue changes ( C )

Article Snippet: More recently, endoscopic management of anterior urethral strictures with the Optilume ® drug-coated balloon (DCB) (Laborie Medical Technologies Corp., Portsmouth, NH) has been studied.

Techniques:

Demographics and outcomes of patients undergoing treatment of RIPUS with the Optilume ® DCB

Journal: BMC Urology

Article Title: Optilume balloon dilation for radiation induced posterior urethral stenosis: a multi-institutional experience

doi: 10.1186/s12894-025-01829-0

Figure Lengend Snippet: Demographics and outcomes of patients undergoing treatment of RIPUS with the Optilume ® DCB

Article Snippet: More recently, endoscopic management of anterior urethral strictures with the Optilume ® drug-coated balloon (DCB) (Laborie Medical Technologies Corp., Portsmouth, NH) has been studied.

Techniques: